The History of NUVISAN

Founded in 1989 as an independent, family-owned contract research organization (CRO), NUVISAN started with bioanalytical laboratory services and PK/PD studies and later expanded to other areas, such as early discovery, safety testing, clinical trial management, and regulatory support. The company has grown significantly since its founding and has expanded its services and capabilities to meet the changing needs of its clients. Today, NUVISAN has more than 1,000 employees and operates in multiple locations in Europe and the United States.


Founding of NUVISAN ICB GmbH and takeover from Bayer of a fully equipped pharmaceutical research unit with 400 workplaces in the field of small-molecule active ingredients.


NUVISAN expands its portfolio to phase II patient trials by acquiring the CRO INAMED in Gauting, near Munich (Germany).


Market entry into chemistry and formulation development. NUVISAN acquires from NESTLÉ SKIN HEALTH parts of the Galderma research activities at Sophia Antipolis (France).


Founding of NUVISAN Inc., a subsidiary of NUVISAN GmbH, in Boston, Massachusetts (USA).


Entry into non-clinical development through the acquisition and integration of the Grafing site (Germany) from long-standing partner Merck KGaA.


Expansion to Waltrop (Germany) by taking over the research institute Essex Pharma from MSD. Integration of large-scale stability programs and services. Expansion into pharmaceutical analysis of hormones, polymers, and large molecules.


Founding as NUVISAN GmbH after the sale of the AAIPharma group of companies to new owners.


The company now trades under the name AAIPharma Deutschland. The company was renamed AAIPharma in the United States at the same time as AAI International.


Takeover by AAI International (Wilmington, NC). The company is a US-based multifunctional contract research organization providing GCP-, GLP- and GMP-related services to the pharmaceutical industry to support early to late product development.


LAB GmbH founded as one of the first German CROs for clinical development in the pharmaceutical industry. In the early clinical phase, the company quickly develops into a full-service provider.